Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: VIAject Clear all
Recruiting Not applicable Interventional

Effect of Physiologic Insulin Administration on Insulin Sensitivity and Cognition

NCT07265323
View directory record Official record
Conditions
Alzheimer s Disease, Alzheimer Blood Biomarkers, Insulin Sensitivity
Interventions
Physiological Insulin Intervention
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 5, 2026, 2:28 PM EDT
Completed Not applicable Interventional Results available

Vitamin D Replacement After Kidney Transplant

NCT00748618
View directory record Official record
Conditions
Kidney Transplantation, Vitamin D Deficiency
Interventions
Standard vitamin D3 treatment, High dose vitamin D3 treatment
Dietary Supplement
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Sep 5, 2026, 2:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Calorie Restricted, Very Low Fat Plant-based Diet and Multi-component Exercise Program on Metabolic Health

NCT02706288
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Weight loss with very low fat plant-based diet and regular exercise
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Sep 5, 2026, 2:28 PM EDT
Active, not recruiting Not applicable Interventional

Can Gut Bacteria Predict Who Benefits Most From Exercise? A Gut Supplement to Help Exercise Non-Responders

NCT07180446
View directory record Official record
Conditions
Obesity &Amp; Overweight
Interventions
Cardiovascular Exercise, Butyrate
Behavioral · Dietary Supplement
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 5, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

NCT01011868
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773 placebo, BI 10773 low dose, BI 10773 high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Sep 5, 2026, 2:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sleep and IR in Transgender Adolescents

NCT05489159
View directory record Official record
Conditions
Sleep Disorder, Insulin Resistance, Gender Dysphoria
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
12 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 5, 2026, 2:28 PM EDT
Withdrawn Phase 4 Interventional

A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk

NCT03585101
View directory record Official record
Conditions
Hepatitis C
Interventions
Elbasvir/grazoprevir
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 5, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy Study of Intranasal Insulin to Treat Tobacco Abstinence Syndrome

NCT01781234
View directory record Official record
Conditions
Tobacco Abstinence Syndrome
Interventions
Intranasal Insulin, Placebo
Drug
Lead sponsor
Ajna Hamidovic
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 9, 2018 · Synced Sep 5, 2026, 2:28 PM EDT
Not listed Phase 1 Interventional

Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes Mellitus

NCT03332849
View directory record Official record
Conditions
Type1 Diabetes Mellitus, Type2 Diabetes Mellitus
Interventions
HM12470
Biological
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 5, 2026, 2:28 PM EDT
Completed Phase 3 Interventional

Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes

NCT00097084
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
28
States / cities
Little Rock, Arkansas • Inglewood, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Sep 5, 2026, 2:28 PM EDT
Completed Phase 1 Interventional Results available

A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available

NCT00785538
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
IMC-A12
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Scottsdale, Arizona • Detroit, Michigan • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 5, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine

NCT03211858
View directory record Official record
Conditions
Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
Interventions
Insulin aspart, NovoLog/NovoRapid, Insulin glargine (HOE901)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
42
States / cities
Little Rock, Arkansas • Concord, California • Escondido, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 5, 2026, 2:28 PM EDT
Recruiting Not applicable Interventional

Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes

NCT05933174
View directory record Official record
Conditions
Type2diabetes
Interventions
Prompt-sheet, Usual education
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
45 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 5, 2026, 2:28 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Resveratrol in Type2 Diabetes and Obesity

NCT01158417
View directory record Official record
Conditions
Type 2 Diabetes, Obesity, Insulin Resistance
Interventions
Placebo, Resveratrol 40 mg oral three times a day, Resveratrol 500 mg oral once daily.
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
20 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Sep 5, 2026, 2:28 PM EDT
Completed Phase 4 Interventional Results available

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

NCT01117350
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Liraglutide, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 75 Years
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
45
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 5, 2026, 2:28 PM EDT
Recruiting Not applicable Interventional

Stand up for Your Health With a Sit-stand Desk

NCT05585190
View directory record Official record
Conditions
Pre Diabetes, Obesity, Metabolic Syndrome, Sedentary Behavior
Interventions
Control, Sit-Stand Desk at Work
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 79 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 5, 2026, 2:28 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans

NCT01375491
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Doxycycline, Placebo
Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 5, 2026, 2:28 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

ADRB3 Signaling Pathway in Human Adipose Tissue

NCT05634174
View directory record Official record
Conditions
Obesity, Prediabetes
Interventions
Mirabegron
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 5, 2026, 2:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Type 2 Diabetes Affect Exercise Induced Improvement in Insulin Sensitivity

NCT02745613
View directory record Official record
Conditions
Insulin Sensitivity/Resistance
Interventions
8 weeks of combined exercise intervention
Other
Lead sponsor
University of Texas, El Paso
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 5, 2026, 2:28 PM EDT
Terminated Not applicable Interventional

Insulin Resistance in Smokers Undergoing Smoking Cessation

NCT00877513
View directory record Official record
Conditions
Cardiovascular Disease, Insulin Resistance
Interventions
Smoking cessation
Behavioral
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
25 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Sep 5, 2026, 2:28 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II)

NCT02959762
View directory record Official record
Conditions
Obesity, Insulin Resistance, Obesity in Diabetes, Nutritional and Metabolic Diseases, Hyperlipidemia, Hyperglycemia, Cardiovascular Diseases
Interventions
Placebo-Control, Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d), High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
8 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Sep 5, 2026, 2:28 PM EDT
Not yet recruiting Phase 2 Interventional

Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease

NCT07756294
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Empagliflozin, Insulin, Insulin Placebo, Empagliflozin Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 5, 2026, 2:28 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

NCT05539872
View directory record Official record
Conditions
Pharmacokinetics, Pharmacodynamics
Interventions
I004, NovoLog
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 5, 2026, 2:28 PM EDT
Completed Early Phase 1 Interventional

Controlled Insulin Delivery: Combining Technology With Treatment

NCT01484457
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Closed-loop session
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Sep 5, 2026, 2:28 PM EDT